HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Capparelli, E. V. Articles by the PACTG 152 Team, Search for Related Content PubMed PubMed Citation Articles by Capparelli, E. V. Articles by the PACTG 152 Team,

Population Pharmacokinetics and Pharmacodynamics of Zidovudine in HIV-Infected Infants and Children

From the University of California, San Diego, School of Medicine, La Jolla, California (Dr. Capparelli, Dr. Connor, Dr. Spector); University of Chicago, Pritzker School of Medicine, Chicago, Illinois (Dr. Englund); Duke University Medical Center, Durham, North Carolina (Dr. McKinney); UMDNJ/New Jersey Medical School, Newark, New Jersey (Dr. Palumbo); Baylor College of Medicine, Houston, Texas (Dr. Baker); and the NIAID/NICHD, Bethesda, Maryland (PACTG 152 Team)

The purpose of this study was to assess the population pharmacokinetics (PK) and pharmacodynamics (PD) of zidovu-dine (ZDV) in infants and children. This evaluation includes 394 subjects who participated in Pediatric AIDS Clinical Trials Group (PACTG) Study 152 and received either ZDV alone or in combination with didanosine. The most significant PK covariate was age, with infants < 2 years of age having reduced size-adjusted clearance. ZDV exposure was weakly related to maximal reduction in immune complex-dissociated (ICD) p24 antigen but not to reduction at 6 months. Mild chronic anemia occurred in 7.6% of subjects with ZDV average concentration < 1.3 [.proportional] M (350 ng/mL) versus in 23.4% subjects with higher ZDV concentrations (p < 0.001). There was a direct linear relationship between hemoglobin and ZDV levels. It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity.

This article has been cited by other articles:

				L. Durand-Gasselin, A. Pruvost, A. Dehee, G. Vaudre, M.-D. Tabone, J. Grassi, G. Leverger, A. Garbarg-Chenon, H. Benech, and C. Dollfus High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2555 - 2563. [Abstract] [Full Text] [PDF]

				A. S. Bergshoeff, P. L. A. Fraaij, C. Verweij, A. M. C. van Rossum, G. Verweel, N. G. Hartwig, R. de Groot, and D. M. Burger Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children J. Antimicrob. Chemother., December 1, 2004; 54(6): 1152 - 1154. [Abstract] [Full Text] [PDF]